verapamil has been researched along with everolimus in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Crowe, A; Lemaire, M | 1 |
| Allison, MJ; Beyer, D; Bizot, MN; Jiang, Q; Kovarik, JM; Schmouder, RL | 1 |
| Dalkalitsis, A; Georgiou, I; Kitsou, C; Kosmas, I; Lazaros, L; Mynbaev, O; Prapas, I; Prapas, N; Tinelli, A; Tzallas, C | 1 |
| Feutry, F; Marliot, G; Pannier, D; Sakji, I; Strobbe, G; Villain, A | 1 |
| Batistatou, A; Dalkalitsis, A; Georgiou, I; Kitsou, C; Kolibianakis, S; Kosmas, I; Markoula, S; Michaelidis, TM; Papageorgiou, K; Papoudou-Bai, A; Pargianas, M; Salta, S; Tarlatzis, BC | 1 |
1 review(s) available for verapamil and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for verapamil and everolimus
| Article | Year |
|---|---|
Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.
Topics: Analysis of Variance; Calcium Channel Agonists; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Everolimus; Humans; Immunosuppressive Agents; Sirolimus; Verapamil | 2005 |
5 other study(ies) available for verapamil and everolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin.
Topics: Animals; Caco-2 Cells; Everolimus; Humans; Immunosuppressive Agents; Intestinal Absorption; Mannitol; Propranolol; Rats; Rats, Wistar; Sirolimus; Verapamil | 1998 |
The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
Topics: Animals; Capillary Permeability; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Everolimus; Female; Organ Size; Ovarian Hyperstimulation Syndrome; Ovary; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Wistar; TOR Serine-Threonine Kinases; Verapamil | 2016 |
Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: A case report.
Topics: Carcinoma, Renal Cell; Drug Interactions; Drug Monitoring; Everolimus; Female; Humans; Immunosuppressive Agents; Kidney Neoplasms; Middle Aged; Verapamil | 2020 |
Follicle inhibition at the primordial stage without increasing apoptosis, with a combination of everolimus, verapamil.
Topics: Animals; Apoptosis; Autophagy; Cell Differentiation; Drug Evaluation, Preclinical; Everolimus; Female; Fertility Preservation; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Ovarian Follicle; Rats; Rats, Wistar; Verapamil | 2020 |